Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study
Dmitriy Zamarin, Robert A. Burger, Michael W. Sill, Daniel J. Powell, Heather A. Lankes, Michael D. Feldman, Oliver Zivanovic, Camille Gunderson, Emily Ko, Cara Mathews, Sudarshan Sharma, Andrea R. Hagemann, Samir Khleif, Carol Aghajanian
Dive into the research topics of 'Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study'. Together they form a unique fingerprint.